Bortezomib was also observed to lead to accumulation of beta catenin protein in a dose- and time-dependent manner without changing the mRNA level in multiple myeloma cell lines, suggesting the effect was at the post-transcriptional level and this accumulation was associated with bortezomib resistance [34]. The gene discussed is CTNNB1; the disease is plasma cell myeloma.